1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Boehringer Ingelheim GmbH – SWOT Framework Analysis

Boehringer Ingelheim GmbH – SWOT Framework Analysis

  • February 2015
  • -
  • Aruvian's R'search
  • -
  • 25 pages

Headquartered in Germany, Boehringer Ingelheim GmbH is a leading manufacturer of pharmaceuticals for both human and animal health. The company specializes in the development of medicines in the areas of cardiovascular disease, diabetes, stroke prevention, benign prostate hyperplasia, and others. Some of the most famous brand names of the company include Zantac, Mucosolvan, Dulcolax, Buscopan, Cymbalta, Pharmaton, Thomapyrin, among others.

SWOT Analysis, is a strategic planning tool used to evaluate the Strengths, Weaknesses, Opportunities, and Threats involved in a project or in a business venture. It involves specifying the objective of the business venture or project and identifying the internal and external factors that are favorable and unfavorable to achieving that objective.

The aim of Aruvian Research’s SWOT analysis is to identify the key internal and external factors that are important to achieving the objective.

Table Of Contents

Boehringer Ingelheim GmbH - SWOT Framework Analysis
A. Executive Summary

B. A Brief Profile of the Company
B.1 History of the Company
B.2 Company Profile
B.3 Business Segment Analysis
B.4 Products and Services
B.5 Financial Analysis

C. SWOT Framework Analysis
C.1 Strengths to Build Upon
C.2 Weaknesses to Overcome
C.3 Opportunities to Exploit
C.4 Threats to Overcome

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Diabetes & Obesity Drug Development Pipeline Review, 2016

Diabetes & Obesity Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Diabetes & Obesity Drug Development Pipeline Review, 2016 Summary The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type ...

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glutamyl Aminopeptidase ...

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glucose Dependent Insulinotropic Receptor (G Protein ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.